OM
BCYC

Opaleye Management’s Bicycle Therapeutics BCYC Stock Holding History

Opaleye Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-175,000
Closed -$7.68M – 48
2022
Q1 		$7.68M Buy
+175,000
New +$8.17M 2.38% 15

Other funds holding BCYC

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Opaleye Management's BCYC Position: Q2 2022 in Review

Opaleye Management sold out of Bicycle Therapeutics (BCYC) in Q2 2022, closing a stake of 175,000 shares — an estimated $7.68M sold.

Opaleye Management first reported a position in BCYC in Q1 2022 and held it in 1 quarter. The position peaked at $7.68M in Q1 2022. 81 funds tracked by Wall St. Rank hold BCYC as of Q2 2022.

  • Opaleye Management reported no remaining Bicycle Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Opaleye Management sold 175,000 Bicycle Therapeutics shares in Q2 2022, an estimated $7.68M.
  • Opaleye Management first reported a position in Bicycle Therapeutics in Q1 2022 and held it in 1 quarter.
  • Opaleye Management's Bicycle Therapeutics position peaked at $7.68M in Q1 2022.
  • 81 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2022.

Based on Opaleye Management's 13F filing for Q2 2022, filed 15 Aug 2022.